<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02077309</url>
  </required_header>
  <id_info>
    <org_study_id>12-027</org_study_id>
    <secondary_id>111/13</secondary_id>
    <secondary_id>2012-003859-12</secondary_id>
    <nct_id>NCT02077309</nct_id>
  </id_info>
  <brief_title>Effect of Linagliptin on Vascular Inflammation in Patients With Type 2 Diabetes Mellitus</brief_title>
  <acronym>Lina-Plaque</acronym>
  <official_title>Linagliptin as a Modulator of Vascular Inflammation in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Examination of the effect of Linagliptin versus placebo for 6 months on vascular inflammation&#xD;
      of the carotic artery and on abdominal adipose tissue inflammation in patients with diabetes&#xD;
      mellitus type 2. The effect will be assessed by FDG-PET scan.&#xD;
&#xD;
      Furthermore the effect of Linagliptin on the vessel wall volume of the carotid artery will be&#xD;
      assessed by MRI scan and biomarkers of vascular inflammation will be analyzed in blood&#xD;
      samples.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As part of the screening a PET-CT scan is executed to examine baseline vascular inflammation&#xD;
      of the carotid artery and to evaluate abdominal adipose tissues inflammation.&#xD;
&#xD;
      Patients who are eligible to participate in the study according to the in- and exclusion&#xD;
      criteria will be randomised in one of the two study arms.&#xD;
&#xD;
      According to the randomisation the patients will receive 5 mg Linagliptin or placebo per day&#xD;
      for a period of 6 months.&#xD;
&#xD;
      To evaluate the effect of Linagliptin versus placebo the vessel wall volume of the artery&#xD;
      will be assessed by MRI scan and the vascular inflammation of the carotid artery by FDG-PET,&#xD;
      furthermore the vascular inflammation will be analyzed by biomarkers in blood samples and the&#xD;
      abdominal adipose tissue inflammation will investigated by subcutaneous adipose tissue&#xD;
      biopsies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    bad recruitment of suitable participants, just 4 patients in one year&#xD;
  </why_stopped>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of linagliptin on vascular inflammation of the carotic artery</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Examination of the effect of 5 mg linagliptin qd versus placebo on vascular inflammation of the carotic artery by FDG-PET in patients with diabetes mellitus within 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of linagliptin on vessel wall volume of the carotid artery</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>Examination of the effect of 5mg linagliptin qd versus placebo on vessel wall volume of the carotid artery by MRI scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of linagliptin on abdominal adipose tissue inflammation</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>Evaluation of the effect of 5mg linagliptin qd versus placebo on abdominal adipose tissue inflammation by FDG-PET in addition to adipose tissue biopsies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of linagliptin on biomarkers of vascular inflammation</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>Blood analysis to examine the effect of linagliptin on biomarkers of vascular inflammation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Diabetes Mellitus Type 2 (T2DM)</condition>
  <condition>Vascular Inflammation</condition>
  <condition>Plaque Morphology</condition>
  <arm_group>
    <arm_group_label>Linagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 5 mg linagliptin once daily for a period of 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will take placebo tablets once daily for a period of 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <arm_group_label>Linagliptin</arm_group_label>
    <other_name>Trade name TrajentaÂ® by Boehringer Ingelheim (BI) Pharma GmbH &amp; Co KG, Biberach, Germany</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Produced by Boehringer Ingelheim (BI) Pharma GmbH &amp; Co KG, Biberach, Germany</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diabetes mellitus Type 2&#xD;
&#xD;
          2. HbA1c &gt; 7%&#xD;
&#xD;
          3. Age &gt; 50 years&#xD;
&#xD;
          4. Coronary artery disease or carotid artery disease&#xD;
&#xD;
          5. 18F-FDG uptake of the carotid arterial wall to background (blood) ratio &gt; 1.8&#xD;
&#xD;
          6. Written informed consent prior to study participation&#xD;
&#xD;
          7. Stable anti-diabetic and cholesterol lowering medication for the last 3 month&#xD;
&#xD;
          8. Stable anti-diabetic medication for the last 6 weeks which should include a maximal&#xD;
             tolerated dose of metformin (unless contraindication or intolerance to metformin does&#xD;
             exist);&#xD;
&#xD;
          9. Indication to increase anti-diabetic medication as judged by the investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diabetes mellitus type 1&#xD;
&#xD;
          2. Use of DPP-4 Inhibitor, GLP-1 agonists, Thiazolindinedione&#xD;
&#xD;
          3. Kidney disease CKD 4 and more (GFR &lt; 30 ml/min/1.73)&#xD;
&#xD;
          4. Liver disease (ALT or AST &gt; 3 times the upper limit of norm) or known liver cirrhosis&#xD;
&#xD;
          5. Any reason for not being able to sustain the imaging studies&#xD;
&#xD;
          6. Pacemaker/ICD/metallic clips in close relation to vessels in the brain&#xD;
&#xD;
          7. Uncontrolled thyroid disease&#xD;
&#xD;
          8. Active malignant disease&#xD;
&#xD;
          9. Chronic inflammatory disease&#xD;
&#xD;
         10. Chronic use of NSAR or cortison&#xD;
&#xD;
         11. HbA1c &gt; 8.5%&#xD;
&#xD;
         12. Recent (&lt;3 months) clinically significant coronary or cerebral vascular event&#xD;
&#xD;
         13. Pregnant females as determined by positive [serum or urine] HCG test at Screening or&#xD;
             prior to dosing&#xD;
&#xD;
         14. Lactating females&#xD;
&#xD;
         15. The subject has a history of any other illness, which, in the opinion of the&#xD;
             Investigator, might pose an unacceptable risk by administering study medication&#xD;
&#xD;
         16. The subject received an investigational drug within 30 days prior to inclusion into&#xD;
             this study&#xD;
&#xD;
         17. The subject has any current or past medical condition and/or required medication to&#xD;
             treat a condition that could affect the evaluation of the study&#xD;
&#xD;
         18. The subject is unwilling or unable to follow the procedures outlined in the protocol&#xD;
&#xD;
         19. The subject is mentally or legally incapacitated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nikolaus Marx, Univ.-Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine I, RWTH Aachen University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Internal Medicine I, University Hospital</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Research Institute Maastricht (CARIM)</name>
      <address>
        <city>Maastricht</city>
        <zip>6229</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>February 28, 2014</study_first_submitted>
  <study_first_submitted_qc>March 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2014</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T2DM,</keyword>
  <keyword>vascular inflammation,</keyword>
  <keyword>18-FDG-PET,</keyword>
  <keyword>plaque morphology,</keyword>
  <keyword>MRI,</keyword>
  <keyword>DPP-4 Inhibition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

